Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 1/20 | 0.36 |
| ▸ | ADH1C | P00326 | 1/20 | 0.36 |
| ▸ | ADH1A | P07327 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9349275 | 0.90 | ALDH1A1 (0.33) | ADH1BADH1CADH1AALDH1A1 | |
| SCHEMBL270003 | 0.87 | ALDH1A1 (0.32) | ADH1BADH1CADH1AALDH1A1 | |
| SCHEMBL10940372 | 0.87 | TSHR (0.34) | ADH1BADH1CADH1ATSHR | |
| SCHEMBL276831 | 0.84 | LMNA (0.36) | — | |
| SCHEMBL11369973 | 0.82 | — | — | |
| SCHEMBL277208 | 0.82 | LMNA (0.52) | ALOX15 | |
| SCHEMBL17620425 | 0.82 | PIK3CD (0.38) | — | |
| SCHEMBL22113926 | 0.80 | KDM4C (0.42) | TSHR | |
| SCHEMBL5828269 | 0.79 | GABRP (0.36) | ALDH1A1 | |
| SCHEMBL277981 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331724-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2023-10-19 | — | — | US | disclosed |
| CN-116813979-A | Nucleating agent, synthetic resin composition containing same, and molded article thereof | 株式会社ADEKA | 2023-09-29 | — | — | CN | disclosed |
| US-11731971-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2023-08-22 | — | — | US | disclosed |
| CN-112839988-B | Nucleating agent, synthetic resin composition containing same, and molded article thereof | 株式会社ADEKA | 2023-06-06 | — | — | CN | disclosed |
| CN-110945083-B | Styrene compound or salt thereof, polarizing film, polarizing plate and display device | 日本化药株式会社 | 2022-07-01 | — | — | CN | disclosed |
| CN-114026199-A | Polarizing luminescent film, polarizing luminescent sheet, and display device containing water-soluble coumarin compound or salt thereof | 日本化药株式会社 | 2022-02-08 | — | — | CN | disclosed |
| US-20210395209-A1 | NUCLEATING AGENT, SYNTHETIC-RESIN COMPOSITION CONTAINING SAME, AND MOLDED OBJECT THEREOF | ADEKA CORPORATION (JP) | 2021-12-23 | — | — | US | disclosed |
| US-20210371419-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2021-12-02 | — | — | US | disclosed |
| US-11117896-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2021-09-14 | — | — | US | disclosed |
| EP-3858909-A1 | NUCLEATING AGENT, SYNTHETIC-RESIN COMPOSITION CONTAINING SAME, AND MOLDED OBJECT THEREOF | ADEKA CORPORATION (JP) | 2021-08-04 | — | — | EP | disclosed |
| EP-0104296-B1 | PROCESS FOR THE PREPARATION OF STILBENE-4,4'-DIALDEHYDE | CIBA-GEIGY AG (CH) | 1985-12-18 | — | — | EP | disclosed |
| US-4477685-A | USING FORMALDEHYDE, CARBON MONOXIDE, AND HYDROGEN | MONSANTO COMPANY (US) | 1984-10-16 | — | — | US | disclosed |
| EP-0104296-A1 | Process for the preparation of stilbene-4,4'-dialdehyde | CIBA-GEIGY AG (CH) | 1984-04-04 | — | — | EP | disclosed |
| EP-0102341-A2 | Improved hydroformylation process to prepare glycol aldehydes | Monsanto Company (US) | 1984-03-07 | — | — | EP | disclosed |
| US-4405814-A | Hydroformylation of formaldehyde with rhodium catalysts | MONSANTO COMPANY (US) | 1983-09-20 | — | — | US | disclosed |
| EP-0078768-A1 | Process for the catalytic Pd arylation of olefines with aryl halogenides | CIBA-GEIGY AG (CH) | 1983-05-11 | — | — | EP | disclosed |
| EP-0002908-B1 | HYDROFORMYLATION OF FORMALDEHYDE WITH RHODIUM CATALYST | MONSANTO COMPANY (US) | 1982-05-12 | — | — | EP | disclosed |
| US-4262140-A | HYDROLYSIS OF METHYL FORMATE, EXTRACTION WITH TERTIARY AMIDE, FRACTIONAL DISTILLATION | BASF AKTIENGESELLSCHAFT (DE) | 1981-04-14 | — | — | US | disclosed |
| EP-0012321-A1 | Process for the obtention of water-free or substantially water-free formic acid | BASF Aktiengesellschaft (DE) | 1980-06-25 | — | — | EP | disclosed |
| EP-0002908-A1 | Hydroformylation of formaldehyde with rhodium catalyst | MONSANTO COMPANY (US) | 1979-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731971-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | ADH1B 2415/4885ADH1C 1370/4885ADH1A 2255/4885 |
| US-20210395209-A1 | NUCLEATING AGENT, SYNTHETIC-RESIN COMPOSITION CONTAINING SAME, AND MOLDED OBJECT THEREOF | NOC2L, RIF1, NAP1L1 | ADH1B 2721/4885ADH1C 3077/4885ADH1A 2850/4885 |
| US-20210371419-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | FN1, BMP1, AZI2 | ADH1B 2415/4885ADH1C 1370/4885ADH1A 2255/4885 |
| US-20230331724-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | FN1, BMP1, AZI2 | ADH1B 2415/4885ADH1C 1370/4885ADH1A 2255/4885 |
| US-11117896-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | ADH1B 2415/4885ADH1C 1370/4885ADH1A 2255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.